Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of EBIT Margin data on record, last reported at 13.98% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 2499.0% year-over-year to 13.98%; the TTM value through Dec 2025 reached 3.25%, up 7384.0%, while the annual FY2025 figure was 3.25%, 7384.0% up from the prior year.
  • EBIT Margin reached 13.98% in Q4 2025 per ARQT's latest filing, up from 8.59% in the prior quarter.
  • Across five years, EBIT Margin topped out at 13.98% in Q4 2025 and bottomed at 14448.0% in Q3 2022.
  • Average EBIT Margin over 4 years is 1565.5%, with a median of 134.81% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 1432499bps in 2023, then surged 2499bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 2310.84% in 2022, then skyrocketed by 80bps to 452.23% in 2023, then soared by 98bps to 11.0% in 2024, then soared by 227bps to 13.98% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 13.98% in Q4 2025, 8.59% in Q3 2025, and 17.93% in Q2 2025.